MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells-Reference-Cited by-同舟云学术

MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells

Published:2016-01-27 Issue:1 Volume:11 Page:e0148093
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Wong Shuit-Mun,Liu Fu-Hwa,Lee Yueh-Lun,Huang Huei-Mei

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory;DT Holyoake;Br J Haematol,2001

2. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis;LS Steelman;Leukemia,2004

3. BCR-ABL in chronic myelogenous leukemia-how does it work?;JM Goldman;Acta Haematol,2008

4. Flying under the radar: the new wave of BCR-ABL inhibitors;A Quintas-Cardama;Nat Rev Drug Discov,2007

5. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib;G Wei;J Hematol Oncol,2010

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemoproteomics Reveals Glaucocalyxin A Induces Mitochondria‐Dependent Apoptosis of Leukemia Cells via Covalently Binding to VDAC1;Advanced Biology;2023-12-17

2. C12, a combretastatin-A4 analog, exerts anticancer activity by targeting microtubules;Biochemical Pharmacology;2019-12

3. New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics;Current Topics in Medicinal Chemistry;2019-07-30

4. Diverse Targeted Approaches to Battle Multidrug Resistance in Cancer;Current Medicinal Chemistry;2019-01-03

5. Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells;PLOS ONE;2017-10-11